Terms: = Leukemia AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Treatment
145 results:
1. BRCC36 associates with FLT3-ITD to regulate its protein stability and intracellular signaling in acute myeloid leukemia.
Liu J; Isaji T; Komatsu S; Sun Y; Xu X; Fukuda T; Fujimura T; Takahashi S; Gu J
Cancer Sci; 2024 Apr; 115(4):1196-1208. PubMed ID: 38288901
[TBL] [Abstract] [Full Text] [Related]
2. Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML.
Wheeler EC; Martin BJE; Doyle WC; Neaher S; Conway CA; Pitton CN; Gorelov RA; Donahue M; Jann JC; Abdel-Wahab O; Taylor J; Seiler M; Buonamici S; Pikman Y; Garcia JS; Belizaire R; Adelman K; Tothova Z
Sci Transl Med; 2024 Jan; 16(728):eade2774. PubMed ID: 38170787
[TBL] [Abstract] [Full Text] [Related]
3. Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination.
Schvartzman JM; Forsyth G; Walch H; Chatila W; Taglialatela A; Lee BJ; Zhu X; Gershik S; Cimino FV; Santella A; Menghrajani K; Ciccia A; Koche R; Sánchez-Vega F; Zha S; Thompson CB
Mol Cell; 2023 Jul; 83(13):2347-2356.e8. PubMed ID: 37311462
[TBL] [Abstract] [Full Text] [Related]
4. Unifying targeted therapy for leukemia in the era of PARP inhibition.
Boila LD; Sengupta A
Exp Hematol; 2023 Aug; 124():1-14. PubMed ID: 37236341
[TBL] [Abstract] [Full Text] [Related]
5. Subcutaneous Microabscesses and Myositis as Part of Immune Reconstitution Inflammatory Syndrome due to Chronic Disseminated Candidiasis in a Child With Acute Lymphoblastic leukemia.
Reddy NA; Addala S; S S S; Lashkari HP
J Pediatr Hematol Oncol; 2023 May; 45(4):e555-e559. PubMed ID: 37083275
[TBL] [Abstract] [Full Text] [Related]
6. Low Expression of brca1 as a Potential Relapse Predictor in B-Cell Acute Lymphoblastic leukemia.
Villegas-Ruíz V; Medina-Vera I; Arellano-Perdomo P; Castillo-Villanueva A; Galván-Diaz CA; Paredes-Aguilera R; Rivera-Luna R; Juárez-Méndez S
J Pediatr Hematol Oncol; 2023 Mar; 45(2):e167-e173. PubMed ID: 36730467
[TBL] [Abstract] [Full Text] [Related]
7. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours.
Barszczewska-Pietraszek G; Drzewiecka M; Czarny P; Skorski T; Śliwiński T
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613762
[TBL] [Abstract] [Full Text] [Related]
8. Wee1 promotes cell proliferation and imatinib resistance in chronic myeloid leukemia via regulating DNA damage repair dependent on ATM-γH2AX-MDC1.
Zeng F; Peng Y; Qin Y; Wang J; Jiang G; Feng W; Yuan Y
Cell Commun Signal; 2022 Dec; 20(1):199. PubMed ID: 36575478
[TBL] [Abstract] [Full Text] [Related]
9. Synergistic effect of combined PI3 kinase inhibitor and PARP inhibitor treatment on BCR/ABL1-positive acute lymphoblastic leukemia cells.
Hiroki H; Akahane K; Inukai T; Morio T; Takagi M
Int J Hematol; 2023 May; 117(5):748-758. PubMed ID: 36575328
[TBL] [Abstract] [Full Text] [Related]
10. [BILATERAL OCULAR PLASMACYTOMA PRESENTING AS ACUTE ANTERIOR UVEITIS].
Sharon Y; Reich E; Hayman L; Kramer M
Harefuah; 2022 Oct; 161(10):606-610. PubMed ID: 36315206
[TBL] [Abstract] [Full Text] [Related]
11. BMI-1 promotes breast cancer proliferation and metastasis through different mechanisms in different subtypes.
Liu JY; Jiang YN; Huang H; Xu JF; Wu YH; Wang Q; Zhu Y; Zheng B; Shen C; Qian WF; Shen J
Cancer Sci; 2023 Feb; 114(2):449-462. PubMed ID: 36285479
[TBL] [Abstract] [Full Text] [Related]
12. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
[No Abstract] [Full Text] [Related]
13. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
DiSilvestro P; Banerjee S; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; McNamara J; Lowe ES; Ah-See ML; Moore KN;
J Clin Oncol; 2023 Jan; 41(3):609-617. PubMed ID: 36082969
[TBL] [Abstract] [Full Text] [Related]
14. Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms.
Baranwal A; Hahn CN; Shah MV; Hiwase DK
Curr Hematol Malig Rep; 2022 Dec; 17(6):254-265. PubMed ID: 35986863
[TBL] [Abstract] [Full Text] [Related]
15. Pneumocystis jirovecii-associated immune reconstitution inflammatory syndrome-like phenomenon in a child with leukaemia: a case report and literature review.
Lei JY; Chen H; Zhou DH; Xu LH; Fang JP; Mai YG
BMC Pediatr; 2022 Jul; 22(1):410. PubMed ID: 35820900
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy and safety of
Clement D; Navalkissoor S; Srirajaskanthan R; Courbon F; Dierickx L; Eccles A; Lewington V; Mitjavila M; Percovich JC; Lequoy B; He B; Folitar I; Ramage J
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3529-3537. PubMed ID: 35389069
[TBL] [Abstract] [Full Text] [Related]
17. Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
Wattebled KJ; Drumez E; Coiteux V; Magro L; Srour M; Chauvet P; Quesnel B; Duhamel A; Yakoub-Agha I; Beauvais D
Ann Hematol; 2022 Jun; 101(6):1321-1331. PubMed ID: 35352216
[TBL] [Abstract] [Full Text] [Related]
18. Hidden in the Eyes-Recurrence of Systemic Hemopathies Reportedly "In Remission": Six Cases and Review of Literature.
Denier M; Tick S; Dubois R; Dulery R; Eller AW; Suarez F; Burroni B; Maurage CA; Bories C; Konopacki J; Puech M; Bouscary D; Cantalloube A; Héron E; Marçais A; Habas C; Theillac V; Keilani C; Bonhomme GR; Gallagher DS; Boumendil J; Abarah W; Sedira N; Bertin S; Choquet S; Sahel JA; Merabet L; Brignole-Baudouin F; Putterman M; Errera MH
Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334633
[No Abstract] [Full Text] [Related]
19. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L
Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933
[TBL] [Abstract] [Full Text] [Related]
20. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
[No Abstract] [Full Text] [Related]
[Next]
